26 results about "Uremia" patented technology

To provide a jelly composition containing spherical adsorptive carbon for improving uremic symptoms and delaying initiation of dialysis of chronic renal failure patients, which has more improved medication compliance than existing therapeutic agents.SOLUTION: The jelly composition contains spherical adsorptive carbon as an active ingredient, a gelling agent, a thickener, and spherical adsorptive carbon containing distilled water.SELECTED DRAWING: Figure 2

The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid-related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I.

The invention provides a preparation process and a use method of a medicinal and edible substance composition. The medicine overcomes the defects that rejection reaction is insufficient when cancer is treated by a stem cell transplantation method and organ lesions cannot be treated simultaneously when cancer is treated by an immune cell method and a vaccine cell method; the oral liquid comprises the following raw materials in parts by weight: 0.1-3.0 parts of cordyceps militaris, 0.1-3.0 parts of fermented cordyceps sinensis powder, 1.0-3.5 parts of pseudo-ginseng, 1.0-2.5 parts of American ginseng, 1.0-1.5 parts of salvia miltiorrhiza powder or ligusticum wallichii, 1.0-3.0 parts of high-quality gastrodia elata and medicinal pure honey which is 0.9-1.3 times of the total weight of the medicinal materials. The preparation method comprises the following steps: mixing prescription raw materials, crushing, adding honey, and preparing honeyed boluses or beverages. The medicine disclosed by the invention is safe, can treat cancers, diabetes mellitus, heart diseases, liver diseases, nephropathy, uremia or entanglement of a plurality of diseases with high curative effect, and enables patients to be young; according to the invention, messy code genes of a patient can be normally edited while the disease is treated.

The application discloses a quantitative-discriminative integrated uremia intelligent detection system, and relates to the field of medical spectrum analysis.The system comprises a spectrum collection module, which is used for collecting near-infrared transmission spectrum data of a serum sample to be measured; and a double-model detection module, which is used for determining urea concentration and a uremia state of the serum sample to be measured by using a pre-constructed urea concentration quantitative regression model and a uremia state discriminative classification model respectively according to the near-infrared transmission spectrum data.The application realizes accurate determination of urea concentration and rapid automatic identification of uremia, and has significant advantages in reducing cost, simplifying process and improving diagnosis efficiency.

The described technology can include methods of treating a population of red blood cells (RBCs) in an individual, particularly a chronic kidney disease (CKD) patient with renal anemia, by reducing the amount of a Piezo1 chemical agonist in the patient's blood. In one embodiment, a method of treating a patient with renal anemia can include increasing RBC lifespan of a population of RBCs in the patient by reducing Piezo1 channel activation duration of at least a portion of the population of RBCs by reducing the amount of a target uremic compound in the patient's blood, the target uremic compound having a form that prolongs Piezo1 channel activation duration, wherein the amount of the target uremic compound can be reduced by selectively removing at least a portion of the target uremic compound from the patient's blood. Other embodiments are also described.

The present invention provides a double-layer hollow fiber membrane for enclosing a hollow space through which blood flows and transporting uremic toxins and waste products from the blood to the outside, and a method for manufacturing the same. The double-layer hollow fiber membrane includes a first layer having first pores and a second layer having second pores. The first pores of the first layer and the second pores of the second layer are connected to each other, and the second pores are open pores connected to the outside. The double-layer hollow fiber membrane can remove uremic toxins with molecular sizes from blood while minimizing the loss of blood components and essential proteins due to the pores increasing in size from the first pores to the second pores.

The invention discloses resin with super-strong adsorption performance as well as a preparation method and application thereof. Macroporous adsorption resin is prepared from a polyvinyl cross-linking agent and a pore-foaming agent, and then a polymer is grafted through residual hanging double bonds. The macroporous adsorption resin prepared by using the method has a huge specific surface area and abundant pore channels, and has super-strong adsorption performance on macromolecular toxins such as parathyroid hormone and beta2-microglobulin in the body of a uremia patient, and in addition, hydroxyethyl polymethacrylate is grafted on the surface of the resin, so that the hemolysis rate is reduced, and the blood compatibility is improved.

The present disclosure relates to stable aqueous solutions comprising high concentrations of an anti-C5 antibody (e.g., ravulizumab) and methods of making the solutions. The present disclosure also provides methods of using the solutions to treat or prevent complement-associated disorders, such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Therapeutic kits containing one or more of the solutions, and means for administering the solutions to a patient in need of such treatment, are also contemplated.

The invention belongs to the technical field of Chinese herbal medicines, and particularly relates to a traditional Chinese medicine herbal composition for preventing and treating diabetic complications and a preparation method thereof. The traditional Chinese medicine herbal composition is prepared from folium mori, radix astragali, radix rehmanniae, radix polygonati officinalis, radix ophiopogonis, rhizoma dioscoreae, poria cocos, radix puerariae, opuntia ficus-indica, inulin, rumex hanus, American ginseng and rhizoma curcumae longae. The traditional Chinese medicinal materials are combined to clean sugar scale micro-crystals in blood vessel microcirculation, improve the functions of liver and pancreas islet, regulate the blood sugar level and enhance the anti-oxidation and self-healing capability of a body, so that the blood sugar is stabilized; the occurrence of diabetic complications such as fundus retinopathy, neuropathy, hypertension, cerebral infarction, myocardial infarction, uremia and gangrene is prevented and controlled. Besides, the traditional Chinese medicine composition is a pure herbal traditional Chinese medicine formula, is high in safety and exact in curative effect, and has a wide application prospect in the field of prevention and treatment of diabetic complications.

The present invention relates to antibodies or antigen-binding fragments thereof, specific for a uremic toxin(s), compositions comprising these antibodies or antigen-binding fragments, and methods of use thereof.

The application provides a traditional Chinese medicine composition for treating uremia and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine compositions. The traditional Chinese medicine composition for treating uremia is prepared from raw materials and is characterized by kidney-tonifying, spleen-strengthening, qi-benefiting, turbidity-removing, dampness-removing and blood-stasis-removing, and is an effective medicine for treating chronic renal failure and is worth popularization and application.

The invention discloses a traditional Chinese medicine compound preparation for treating nephrotic syndrome and a preparation method of the traditional Chinese medicine compound preparation, and belongs to the technical field of nephrotic syndrome treatment.The synbiotic microcapsule is prepared by compatibility of traditional Chinese medicines such as safflower, scutellaria baicalensis and perilla frutescens, and the synbiotic microcapsule is prepared by embedding traditional Chinese medicine extracts such as astragalus membranaceus and lily with lactobacillus acidophilus and bifidobacterium; and the wall material is prepared from mannose grafted meadowfoam seed extract, sodium alginate and fucoidin sulfate. The synbiotics microcapsule utilizes a Maillard reaction modified wall material to enhance gastric acid erosion resistance, realizes intestinal targeted colonization through mannose residues, protects probiotics, directionally releases traditional Chinese medicine active components, adjusts intestinal flora balance and inhibits uremia toxin generation. The traditional Chinese medicine components such as the safflower and the scutellaria baicalensis improve kidney blood circulation, relieve inflammatory response and regulate lipid metabolism by inhibiting an NF-kappa B channel, activating an AMPK channel and the like; the components such as the Chinese yam and the Chinese wolfberry can repair the permeability of glomerular basement membrane and improve the hypoproteinemia.

The invention discloses a traditional Chinese medicine formula for preventing and treating diabetic nephropathy. The important composition is prepared from the following raw material medicines: 100g of gynura divaricata, 100g of silybum marianum seeds, 100g of clerodendranthus spicatus, 60g of melastoma dodecandrum, 60g of horseradish tree leaves, 60g of sappan wood, 60g of pseudo-ginseng, 60g of ligusticum chuanxiong hort, 60g of leech, 60g of gardenia jasminoides, 60g of sweet potato pulp, 60g of centella asiatica and 60g of cottonrose hibiscus leaves. The traditional Chinese medicine composition is prepared into pills and granules, is a pure traditional Chinese medicine preparation, and has a special effect on treating the diabetic complication kidney. The traditional Chinese medicine composition can effectively inhibit and degrade blood muscle liver, urea nitrogen and blood toxins, can gradually restore the renal function of some mild and moderate diabetic nephropathy patients to normal, and can replace hemodialysis or reduce the number of dialysis times for some severe uremia patients.

The embodiment of the invention provides a cerebral apoplexy risk prediction system applied to uremia patients and a computer device, and the cerebral apoplexy risk prediction system comprises an acquisition unit which is used for respectively acquiring basic physiological index data, first real-time physiological data, dialysis effect data and a second real-time physiological data set; the first prediction unit is used for predicting a first cerebral apoplexy occurrence risk value in the dialysis process through a first prediction model; the second prediction unit is input into a second prediction model to predict and obtain a second cerebral apoplexy occurrence risk value; and the switching unit responds to a switching signal representing entering or exiting of the dialysis process to correspondingly switch and use the first prediction unit or the second prediction unit. Different prediction models are adopted in stages, the cerebral apoplexy risk is predicted according to different physiological data changes of uremia patients in the dialysis process and after dialysis is finished, and then the timeliness and accuracy of risk prediction are improved.

A method of performing dialysis includes: recirculating a dialysis fluid from a patient or a dialyzer for at least two cycles, each cycle contacting the dialysis fluid first with a zirconium phosphate layer followed by at least one of a urease layer, a zirconium oxide layer, or a carbon layer; storing the recirculated dialysis fluid in a storage container; and transferring the dialysis fluid from the storage container to the patient or the dialyzer. In one example, the zirconium phosphate layer and the at least one of the urease layer, the zirconium oxide layer, or the carbon layer is provided by a sorbent cartridge.

The present disclosure is directed to hemodialysis membranes. In particular, the present disclosure relates to hemodialysis membranes comprising uremic metabolites and zwitterionic moieties, and methods of hemodialysis thereof.

The present invention relates to a new process for the preparation of heterocyclic derivative compounds of Formula I; to new intermediate compounds used in said process for the preparation; to compositions for the treatment or prevention of hyperuricemia, gout disease, nephritis, chronic renal failure, kidney stones, uremia, urinary stones or uric acid-related diseases, said compositions comprising a compound of Formula I at a dosage of administration of more than 2 mg to 10 mg below, administered orally once a day; and to new hydrochloride 1.5 hydrate salts of compounds of Formula I.

This invention discloses an adaptive operation optimization method and system for hemodialysis equipment based on multimodal sensing and clearance efficiency prediction, belonging to the field of equipment control technology. This invention uses multispectral optics and a micro-mass spectrometry module to non-invasively monitor the molar enrichment of uremic solutes in dialysis waste fluid in real time, and constructs a multimodal feature vector by combining blood flow, pressure, and adsorption attenuation coefficients; it establishes a baseline for equipment and consumable performance based on a solute transport-membrane mass transfer coupled kinetic model, achieving real-time assessment and trend prediction of clearance efficiency; it adaptively adjusts flow rate, time window, and filtration mode according to operating status, automatically compensates for consumable performance degradation, stabilizes clearance efficiency, and predicts consumable lifespan to support preventative maintenance. This invention optimizes only equipment operation, has strong adaptive capabilities, and is stable and reliable in operation, applicable to various combined blood purification treatment devices.

The present invention provides an activated carbon adsorbent for oral administration, wherein the activated carbon adsorbent is in the form of particles obtained by carbonization and subsequent activation of poly(styrene-co-divinylbenzene) particles, wherein the poly(styreneco-divinylbenzene) particles are macroporous and have a moisture content of from about 5 wt% to about 60 wt% relative to the total mass of the poly(styrene-co- divinylbenzene) particles. The present invention also provides an activated carbon adsorbent for oral administration, wherein the activated carbon adsorbent is in the form of particles, comprises micropores and mesopores, and has a total surface area of at least about 1000 m2 / g and a total pore volume of at least about 1 cm3 / g, wherein at least about 50% of the total pore volume is formed by the micropores, and at least about 20% of the total pore volume is formed by the mesopores. The present disclosure also provides a pharmaceutical composition comprising an activated carbon adsorbent of the present invention, and an in vitro method of removing one or more uremic toxins from a fluid using an activated carbon adsorbent of the present invention. As disclosed herein, the activated carbon adsorbents also find utility in the treatment of a renal disease or a liver disease.

The present invention relates to compositions for reducing or avoiding uremic toxin accumulation in cardiovascular metabolism or neurodegenerative disorders, in particular compositions comprising probiotics, prebiotics (carbohydrates or fibres) and lipids.

The invention provides an application of catechin as a diagnostic target in preparation of a uremic pruritus diagnostic product, and relates to the technical field of biomedicine, the technical key points are as follows: in the application, uremic pruritus micromolecular substances are found by using serum of a uremic patient to carry out a non-targeted metabonomics technology, and generally, the application of catechin as a diagnostic target in preparation of a uremic pruritus diagnostic product has a good clinical application prospect. Metabolic profiles of serum from human subjects diagnosed with uremic pruritus, including pre-dialysis pruritus, post-dialysis transient remission, and non-remission of pre-dialysis pruritus, are determined. Metabolic profiles from the two groups of biological samples are compared, and differential molecules exist in the metabolic profiles from the two groups of patients suffering from uremic pruritus. According to the invention, through non-targeted metabonomics, a significantly different molecule catechin which the pruritus of a uremia patient is not relieved before and after dialysis and the pruritus is temporarily relieved after dialysis is screened out, the catechin is injected into the cheek part of a normal mouse, and the pruritus conditions of the two mouse models are detected through behavioristics. And the evidence of mouse pruritus caused by the catechin is provided through a verification test.

The present invention provides, inter alia, methods of treating a pruritic or inflammatory skin disease or disorder, or pruritus associated with a certain disease or disorder, using anti-OSMR [beta] antibodies, comprising methods of treating pruritus associated with atopic dermatitis, chronic kidney disease-associated pruritus, uremic pruritus or prurigo nodularis, chronic idiopathic pruritus, chronic idiopathic urticaria, chronic spontaneous urticaria, skin amyloidosis, chronic simple moss, psoriasis plaque, moss planus, inflammatory lepidosis, and the like. The present invention relates to methods for treating mastocytoplasia and bullous pemphigus, comprising the step of administering an anti-OSMR [beta] antibody to a subject in need of treatment at a therapeutically effective dose and administration interval relative to a control for a treatment cycle sufficient to ameliorate, stabilize, or alleviate one or more symptoms of the disease or condition.

The present invention relates to a composition for preventing, ameliorating, or treating kidney and liver diseases, comprising a complex (NEPROBIN) of Ganoderma lucidum extract and Robinia pseudoacacia flower extract as an active ingredient. The complex provided from the present invention exhibits excellent effects in preventing kidney damage, maintaining kidney function, and regenerating kidney tissue by means of inhibition of NO production, reduction in cytokine (TNF-a) and Crp gene expression, increase in glutathione, reduction in ROS production, and increase in uremic toxin excretion, and exhibits excellent effects in preventing liver damage and improving liver function by means of inhibition of NO production, reduction in cytokine (IL6) and MCP1 and CXCL1 gene expression, increase in glutathione, suppression of expression of fibrosis markers (ACTA2, Vim, COL3A1) of hepatic stellate cells, restoration of GSH in liver tissue, increase in antioxidant enzyme activity, and suppression of expression of antiinflammatory- and antifibrotic-related genes and proteins, and thus, the complex is applicable as a pharmaceutical composition for preventing or treating kidney and / or liver diseases, and as a health functional food and food composition for preventing or ameliorating liver diseases.

This invention relates to a dialysis apparatus which ultra-filters blood and to a related method of ultra-filtering blood ex-vivo.More preferably the invention relates to haemodiafiltration using protein-losing membranes and a secondary ultrafiltration and partial re-infusion of haemodiafiltrate for increasing extraction of middle molecules and protein bound uraemic toxins and reducing albumin loss.

The invention provides application of a cadechin-mediated signal channel in treatment of uremic pruritus, relates to the technical field of biomedicine, provides application of the cadechin-mediated signal channel as a drug target in preparation of drugs for treatment of uremic pruritus, and firstly provides establishment of a uremic pruritus model. The establishment of the optimal model verifies that the subsequent inhibition pathway relieves uremic itching. Secondly, a cell model is also established in the application, and the existence of a TRPV1-catchin signal channel is proved in a TRPV1 overexpressed primary cell DRG and a cell line HEK293T by applying calcium imaging, a probe and other technologies to verify the TRPV1 overexpressed primary cell DRG and the cell line HEK293T; wT and a TRPV1-KO mouse are adopted to establish an itching model, and existence of a TRPV1-catchin signal channel in an animal is verified. Finally, according to the application, different doses of dihydroquercetin solutions are injected through caudal veins to detect that uremic pruritus is relieved by inhibiting a TRPV1-catchin signal channel.

The invention discloses a preparation method of hypercrosslinked macroporous adsorption resin for removing protein binding toxins and medium and macromolecular toxins in blood purification. The preparation method comprises the following steps: preparing macroporous styrene-divinylbenzene resin with low crosslinking degree from styrene and divinylbenzene, then carrying out secondary crosslinking on the macroporous styrene-divinylbenzene resin with low crosslinking degree by utilizing a Friedel-Grafts method to prepare the hypercrosslinked adsorption resin, and blocking residual chloromethyl through aromatic hydrocarbon. The hypercrosslinked adsorption resin prepared by the invention has a huge specific surface area and abundant pore channels, and has superstrong adsorption performance on protein binding toxins represented by indoxyl sulfate and medium and macromolecular toxins represented by beta2-microglobulin, and meanwhile, the adsorption performance of the hypercrosslinked adsorption resin is further improved by aromatic hydrocarbon end capping; in addition, the amount of residual chloromethyl can be remarkably reduced, the PH value of a preserving fluid after the adsorbent is made into a perfusion device is greatly increased, and the blood compatibility is improved.